Morphea after initiation of dupilumab in two pediatric atopic dermatitis patients

Abstract

Morphea is a rare multifactorial autoimmune disorder characterized by a complex and dynamic interplay between Th1 and Th2 signaling. Active clinical trials are currently investigating the safety and efficacy of dupilumab for the treatment of primary morphea. Here, we present two cases of morphea that developed in pediatric atopic dermatitis patients treated with dupilumab. These findings may support a causal relationship between IL‐4 receptor blockade and the development of the early inflammatory phase of morphea.